Tags

  • Sorting

  • Filters

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

On April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule regulating laboratory developed tests (LDTs) as in vitro diagnostic devices (IVDs) under the Federal Food, Drug and Cosmetic Act (FD&C Act). This rule amends FDA’s regulations to state that in vitro diagnostic tests “manufactured” by clinical laboratories fall within the scope of the FDA regulatory oversight and is poised to dramatically shift the way clinical diagnostic laboratories in the United States develop and offer LDTs in the future. Read this blog post for a basic overview of the scope, intent and implications of this final rule, including the regulatory requirements, exceptions and timeline for implementation.

Unlock the benefits of nominal mass spectrometry for NPS analysis

The development of analytical methods for the detection and quantitation of drugs and metabolites in a range of biological matrices is a challenging process. Forensic toxicology labs need a reproducible and reliable methodology to ensure the robustness of the data and the quality of the results. They also need robust and sensitive instrumentation that can detect drugs at trace levels with high specificity, especially when it comes to novel psychoactive substances (NPS), which can be difficult to monitor and control.

6 Signs it’s time for a new vendor

6 Signs it’s time for a new vendor

A lab’s success depends on many factors from instrument quality to efficient operations, including being partnered with the right vendor. A vendor is more than just a supplier. They should provide you with a high-level quality of support in maximizing the lifespan and performance of your systems, reducing downtime, enhancing ROI and more. How do you know if you’re partnered with the right one? Here are six signs it might be time to find someone new.

Nitrosamines: Where are we now?

Nitrosamines: Where are we now?

Nitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

On April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule regulating laboratory developed tests (LDTs) as in vitro diagnostic devices (IVDs) under the Federal Food, Drug and Cosmetic Act (FD&C Act). This rule amends FDA’s regulations to state that in vitro diagnostic tests “manufactured” by clinical laboratories fall within the scope of the FDA regulatory oversight and is poised to dramatically shift the way clinical diagnostic laboratories in the United States develop and offer LDTs in the future. Read this blog post for a basic overview of the scope, intent and implications of this final rule, including the regulatory requirements, exceptions and timeline for implementation.

Guide decisions during cell line development with more information at the intact level

Guide decisions during cell line development with more information at the intact level

Monitoring product quality attributes (PQAs) throughout monoclonal antibody (mAb) development is vital to ensuring drug safety and efficacy. By adopting orthogonal analytical techniques and integrating new technologies that have the potential to provide more information, it is possible to improve product quality and manufacturing efficiency and make more informed decisions.

Unlock the benefits of nominal mass spectrometry for NPS analysis

Unlock the benefits of nominal mass spectrometry for NPS analysis

The development of analytical methods for the detection and quantitation of drugs and metabolites in a range of biological matrices is a challenging process. Forensic toxicology labs need a reproducible and reliable methodology to ensure the robustness of the data and the quality of the results. They also need robust and sensitive instrumentation that can detect drugs at trace levels with high specificity, especially when it comes to novel psychoactive substances (NPS), which can be difficult to monitor and control.

The honey sting

The honey sting

As a consumer it’s hard for me not to feel inundated with claims that our food is “all-natural” or “chemical-free” or that we should buy certain “superfoods” for their health benefits.  We read labels and trust that the product we are buying is what we are truly...

Full, partial and empty capsid ratios for AAV analysis: What’s the big deal?

Full, partial and empty capsid ratios for AAV analysis: What’s the big deal?

For many of you working to develop gene therapy drugs, you know that the time to market the drug is critical. Because gene therapeutics cure diseases by targeting specific genes, it is a constant race to see who develops the drug first. Unlike other classes of drugs where multiple medications can be used to treat a disease, whoever is first to develop a gene therapy drug wins.

A rising star in food allergen research: proteomics of shellfish allergen

A rising star in food allergen research: proteomics of shellfish allergen

It’s important to know what you’re eating, especially if you suffer from a food allergy.

About 220 million people worldwide live with a food allergy.1 These numbers, along with the complexity and severity of conditions, continue to rise. In America, there are about 32 million food allergy sufferers—5.6 million of those are children under the age of 18.2.2 That’s 1 out of every 13 children, or about 2 in every classroom. From a financial perspective, the cost of food allergy childcare for US families is up to $25 billion

Routine cannabis screening is here. Will your lab reap the benefits?

Routine cannabis screening is here. Will your lab reap the benefits?

Fast, accurate, and robust solution for routine commercial cannabis testing

As the world debates cannabis legalization for therapeutic applications and recreational use, the trends are shifting.  Medicinal use of cannabis is legal in an increasing number of countries worldwide, including 33 states and the District of Columbia in the United States. Uruguay was the first country in the world to legalize the sale, cultivation, and distribution of cannabis in 2013. In the United States, Washington and Colorado were the first to fully legalize cannabis in 2012. By the end of 2019, 10 states have legalized recreational use for adults over the age of 21, with 64% of Americans favoring the move

Mysterious Vaping Detectives Part 2

Mysterious Vaping Detectives Part 2

In our last blog, I gave you some current highlights about the mysterious vaping illness that was making headlines (and still is). The condition now known as, e-cigarette or vaping, product use-associated lung injury (EVALI) has sickened thousands and killed 57...

Turbo charging your LC-MS/MS analysis

Turbo charging your LC-MS/MS analysis

Would you like to take your LC-MS/MS analysis from 0 to 3 mL/min without the complexity of changing probes or splitting the LC flow? Then take a look into the Turbo V ion source from SCIEX. Introduced more than 15 years ago, the Turbo V ion source continues to be a...

Wordpress Social Share Plugin powered by Ultimatelysocial